Physician profile
Gabrielle Grinstein
NPI 1972563351
$5,243.82
in general payments reported to CMS, 2019-2025
11 companies · $4,016 in 2025
The $4,016 reported for 2025 was more than what 81% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.09 · 2022: $114 · 2023: $65.08 · 2024: $1,035 · 2025: $4,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,600 · Food and Beverage: $1,007 · Travel and Lodging: $509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,600.00 |
| Food and Beverage | $1,007.27 |
| Travel and Lodging | $509.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $4,539.01 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $227.05 | 2022-2025 | Skytrofa |
| Biomarin Pharmaceutical INC. | $123.21 | 2024 | Voxzogo 1.2mg |
| Abbvie INC. | $96.23 | 2024-2025 | |
| Tolmar, INC. | $72.69 | 2023-2024 | |
| Endo USA, INC. | $46.39 | 2025 | Supprelin |
| Novo Nordisk INC | $39.58 | 2024-2025 | Sogroya |
| Azurity Pharmaceuticals, INC. | $39.58 | 2023-2025 | Triptodur, Triptodur |
| Alexion Pharmaceuticals, INC. | $29.65 | 2025 | Strensiq |
| Sandoz INC. | $17.34 | 2025 | Omnitrope |
| Arbor Pharmaceuticals, INC. | $13.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabrielle Grinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.